US researchers have published a proof of concept on the efficacy of human monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in laboratory conditions, as well as their pioneering use in a mouse model. The study is available on the preprint server bioRxiv*. Basic virology research of SARS-CoV-2 is of utmost importance during…
COVID-19 has earned a reputation for being a highly infectious virus, and a new study only emphasizes that.The study, which was published Tuesday in the Proceedings of the National Academy of Sciences, recruited volunteers and asked them to repeat the phrase “stay healthy” several times into the open end of a cardboard box. While they were…
City officials on Monday unveiled a dial that shows the perceived risk of COVID-19 in Lincoln. City officials on Monday unveiled a dial that shows the perceived risk of COVID-19 in Lincoln and the surrounding area. The COVID-19 Risk Dial provides a summary of current conditions in the Lincoln-Lancaster County community. Each color incorporates federal…
Once the coronavirus pandemic is over, we must work out how to stop the spread of poor information that has helped make a bad situation that much worse Health | Leader 6 May 2020 Zubada/Getty Images THE covid-19 pandemic has upended many of the things that we once took for granted, but perhaps the most…
What to know about coronavirus immunity As coronavirus restrictions around the world are being lifted, a new report warns the pandemic that has already killed more than 230,000 people likely won't be contained for two years. The modeling study from the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota also says that…
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/123652" on this server. Reference #18.d494d817.1793332899.22e6a54f https://errors.edgesuite.net/18.d494d817.1793332899.22e6a54f